Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Non-Current Assets data on record, last reported at $25.4 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 162.85% year-over-year to $25.4 million; the TTM value through Sep 2025 reached $69.9 million, changed N/A, while the annual FY2024 figure was $14.0 million, 67.68% up from the prior year.
  • Non-Current Assets reached $25.4 million in Q3 2025 per ZBIO's latest filing, up from $14.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $25.4 million in Q3 2025 and bottomed at $8.4 million in Q4 2023.
  • Average Non-Current Assets over 3 years is $14.6 million, with a median of $14.3 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: soared 67.68% in 2024, then skyrocketed 162.85% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $8.4 million in 2023, then skyrocketed by 67.68% to $14.0 million in 2024, then soared by 80.68% to $25.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $25.4 million in Q3 2025, $14.5 million in Q2 2025, and $16.0 million in Q1 2025.